Thus, orally-administered small molecule NHE3 inhibitors, such as AVE0657 [113] and AZD1722 (Tenapanor), have shown potent effects on the blockage of either renal or intestinal afferent Na+ absorption and control of hypertension [115]. Here, SLC9A3 is linked to Hypertension.